Henan Lingrui Pharmaceutical Co Ltd (600285) — Capital Reinvestment Ratio
Henan Lingrui Pharmaceutical Co Ltd (600285) has a Capital Reinvestment Ratio of 0.04x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥140.12 Million) in capital expenditures (CN¥5.61 Million). See how much free cash does Henan Lingrui Pharmaceutical Co Ltd generate to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Henan Lingrui Pharmaceutical Co Ltd Capital Reinvestment Ratio (1999–2025)
This chart tracks Henan Lingrui Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 26 annual periods.
Annual Capital Reinvestment Ratio for Henan Lingrui Pharmaceutical Co Ltd (1999–2025)
Year-by-year Capital Reinvestment Ratio for Henan Lingrui Pharmaceutical Co Ltd from 1999 to 2025. For live market cap and broader valuation context, see market value of Henan Lingrui Pharmaceutical Co Ltd.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.10x | CN¥553.88 Million | CN¥56.83 Million | ▼ -21.9% |
| 2024 | 0.13x | CN¥875.86 Million | CN¥115.11 Million | ▲ +404.3% |
| 2023 | 0.03x | CN¥813.43 Million | CN¥21.20 Million | ▼ -19.4% |
| 2022 | 0.03x | CN¥834.91 Million | CN¥26.99 Million | ▼ -64.4% |
| 2021 | 0.09x | CN¥845.69 Million | CN¥76.91 Million | ▼ -43.0% |
| 2020 | 0.16x | CN¥450.53 Million | CN¥71.82 Million | ▲ +21.5% |
| 2019 | 0.13x | CN¥450.15 Million | CN¥59.04 Million | ▲ +9.7% |
| 2018 | 0.12x | CN¥436.25 Million | CN¥52.14 Million | ▼ -95.1% |
| 2017 | 2.43x | CN¥105.97 Million | CN¥257.55 Million | ▼ -29.5% |
| 2016 | 3.45x | CN¥63.26 Million | CN¥218.05 Million | ▲ +541.7% |
| 2015 | 0.54x | CN¥156.82 Million | CN¥84.23 Million | ▼ -34.6% |
| 2014 | 0.82x | CN¥124.32 Million | CN¥102.10 Million | ▼ -37.4% |
| 2013 | 1.31x | CN¥127.27 Million | CN¥166.88 Million | ▼ -79.9% |
| 2012 | 6.51x | CN¥15.43 Million | CN¥100.53 Million | ▲ +312.7% |
| 2011 | 1.58x | CN¥40.49 Million | CN¥63.90 Million | ▲ +364.2% |
| 2009 | 0.34x | CN¥132.61 Million | CN¥45.08 Million | ▼ -55.8% |
| 2008 | 0.77x | CN¥43.72 Million | CN¥33.63 Million | ▼ -72.6% |
| 2007 | 2.81x | CN¥15.99 Million | CN¥44.84 Million | ▲ +353.4% |
| 2006 | 0.62x | CN¥26.76 Million | CN¥16.56 Million | ▲ +8.0% |
| 2005 | 0.57x | CN¥33.43 Million | CN¥19.15 Million | ▼ -50.0% |
| 2004 | 1.14x | CN¥35.51 Million | CN¥40.65 Million | ▼ -33.3% |
| 2003 | 1.72x | CN¥23.79 Million | CN¥40.81 Million | ▲ +120.3% |
| 2002 | 0.78x | CN¥69.41 Million | CN¥54.06 Million | ▼ -92.9% |
| 2001 | 10.93x | CN¥3.41 Million | CN¥37.29 Million | ▲ +6.1% |
| 2000 | 10.31x | CN¥3.66 Million | CN¥37.76 Million | ▲ +778.6% |
| 1999 | 1.17x | CN¥4.81 Million | CN¥5.64 Million | — |